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ABSTRACT
Pediatric spinal ependymomas (SEPN) are important albeit uncommon malignant 
central nervous system tumors with limited treatment options. Our current knowledge 
about the underlying biology of these tumors is limited due to their rarity. To begin 
to elucidate molecular mechanisms that give rise to pediatric SEPN, we compared 
the transcriptomic landscape of SEPNs to that of intracranial ependymomas using 
genome-wide mRNA and microRNA (miRNA) expression profiling in primary tumour 
samples. We found that pediatric SEPNs are characterized by increased expression 
of genes involved in developmental processes, oxidative phosphorylation, cellular 
respiration, electron transport chain, and cofactor metabolic process. Next, we 
compared pediatric spinal and intracranial ependymomas with the same tumours in 
adults and found a relatively low number of genes in pediatric tumours that were 
shared with adult tumours (12.5%). In contrast to adult SEPN, down-regulated genes 
in pediatric SEPN were not enriched for position on chromosome 22. At the miRNA 
level, we found ten miRNAs that were perturbed in pediatric SEPN and we identified 
regulatory relationships between these miRNAs and their putative targets mRNAs 
using the integrative miRNA-mRNA network and predicted miRNA target analysis. 
These miRNAs include the oncomiR hsa-miR-10b and its family member hsa-miR-
10a, both of which are upregulated and target chromatin modification genes that are 
down regulated in pediatric SEPN. The tumor suppressor, hsa-miR-124, was down 
regulated in pediatric SEPN and it normally represses genes involved in cell-cell 
communication and metabolic processes. Together, our findings suggest that pediatric 
SEPN is characterized by a distinct transcriptional landscape from that of pediatric 
intracranial EPNs or adult tumors (both SEPNs and intracranial EPNs). Although 
confirmatory studies are needed, our study reveals novel molecular pathways that 
may drive tumorigenesis and could serve as biomarkers or rational therapeutic 
targets.
INTRODUCTION
Ependymomas (EPNs) are primary tumours of the 
central nervous system (CNS) that affect both children 
and adults [1]. They account for 8-10% of CNS tumors 
in children and approximately 4% of adult CNS tumors 
[2, 3]. Current treatment strategies for malignant EPNs 
include maximal surgical resection, radiation therapy, and 
chemotherapy [4]. However, the benefits of chemotherapy 
following surgery remain unclear. Unfortunately, children 
with EPN have a relatively poor prognosis with a 5-year 
progression-free survival rate of only 14%, whereas 
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the 5-year disease-free survival in adults with EPN 
approximates 70% [5]. EPNs are histologically classified 
into three major subtypes according to the World Health 
Organization (WHO), including: myxopapillary EPN or 
subependymoma (grade I), EPN (grade II), and anaplastic 
EPN (grade III) [6]. Current prognostic factors for EPNs 
are based on clinical and histological criteria, such as 
extent of tumor resection and histological grade [7]. 
Complete surgical resection is not always achieved and 
studies to investigate the prognostic value of the WHO 
grading system have yielded conflicting results. Therefore, 
there is an important and unmet need to delineate the 
cellular and molecular pathogenesis of EPNs in order to 
develop more robust prognostic signatures and to identify 
new therapeutic targets to improve outcomes.
EPNs develop throughout the entire CNS but occur 
predominantly in intracranial and spinal cord regions. 
Intracranial EPNs, especially from the posterior fossa 
(PF), are frequently found in children, whereas EPNs from 
the spine are more common in adults [8]. Histologically, 
EPNs within each of these anatomical locations have 
similar morphology, although recent genomic studies 
suggest that their molecular landscapes differ [9–11]. 
For example, PF EPNs represent at least three distinct 
subgroups based on DNA methylation profiles, including: 
1) group A (PF-EPN-A), 2) group B (PF-EPN-B), and 3) 
subependymomas (PF-SE). Supratentorial (ST) EPNs can 
be further classified into subependymoma (ST-SE) and 
two subgroups characterized by fusion genes, including, 
C11orf95-RELA (ST-EPN-RELA) or YAP1-MAMLD1 
(ST-EPN-YAP1). Similarly, spinal ependymomas have 
been grouped into three molecular subgroups that appear 
to correlate with their histologic subtype, including: 
subependymomas (SP-SE), myxopapillary ependymoma 
(SP-MPE), and ependymoma (SP-EPN). The recent 
WHO 2016 classification has reflected these changes by 
incorporating the ST-EPN-RELA subgroups as a distinct 
entity [12]. Mutations in the neurofibromatosis type 2 
(NF2) gene or monozygosity of chromosome 22q were 
previously associated with SEPNs [13], but were limited 
to the SP-EPN subgroup and comprised predominantly 
of adult ependymomas. These genetic alterations are not 
exclusive to SEPNs as the loss of 22q was also observed 
in several other intracranial subgroups [10]. It should be 
emphasized that the number of pediatric SEPNs in the 
DNA methylation-based subgroup analysis is very low 
(n=2) compared to the adult SEPNs (n=53) [10]. Studies 
using gene expression profiling uncovered a number of 
genes and characteristic pathway alterations in SEPNs, 
including HOX genes family, CNS development and 
morphogenesis, angiogenesis, blood coagulation and glial 
cell differentiation [10, 11, 14]. However, the vast majority 
of these studies focused on spinal tumors from adult 
patients. Although prior research indicates that SEPNs are 
distinct from intracranial ependymomas [14, 15], there 
are no studies comparing SEPN in children. Importantly, 
existing epidemiologic data suggest that tumor location, 
genetic lesions, and outcomes differ between children 
and adults, thus underscoring the need for further study 
to elucidate the underlying biology and identify optimal 
treatment approaches for children with SEPN.
Unlike adults where ependymomas occur primarily 
in the spine, in children, SEPN constitutes less than 
10% of all ependymomas. Moreover, SEPN in pediatric 
patients is more likely to be aggressive with higher rates 
of local recurrence and CNS metastasis, compared to 
adults [16]. Because these tumours are uncommon, the 
molecular basis of pediatric SEPN is poorly characterized. 
We hypothesized that elucidation of transcriptomics in 
pediatric ependymomas, specifically evaluating spinal 
and intracranial EPN, would be key to understanding the 
biology of these tumors.
RESULTS
Differential expression of genes defines 
pediatric SEPN
To identify molecular mechanisms underlying 
pediatric SEPN (pSEPN), we compared gene expression 
profiles of spinal (n = 6) and intracranial tumors (PF/ST, 
n = 30/30) from pediatric ependymoma patients (data set 
1, DS1), selecting genes at a false discovery rate (FDR) 
< 0.05. We used an empirical Bayesian moderated t-test, 
which was previously shown to perform robustly on 
unbalanced microarray dataset. We identified a total of 557 
differentially expressed genes between pediatric SEPN 
and intracranial ependymoma (Supplementary Table 1). 
Among them, 82% (455) of genes were over-expressed, 
while 102 were under-expressed in pSEPN (Figure 1A). 
This differential gene expression was consistent when 
we applied a nonparametric rank product method. The 
correlation between rank-product sum statistics and 
t-statistics from the empirical Bayesian method was 
high (|r| = 0.90 when pSEPN > intracranial EPN and |r| 
= 0.85 when pSEPN < intracranial EPN) and majority 
of the differentially expressed genes (90% of 455 over-
expressed and 97% of 102 under-expressed) were within 
the top 15% of rank-product sum statistics (Supplementary 
Figure 1). We next investigated the effect of sample 
imbalance on differential expression. We randomly 
picked six samples each from PF/ST and performed 
differential expression analysis with samples from SP. 
We used an empirical Bayesian moderated t-test on equal 
number of samples and repeated this analysis with 100 
different permutations of PF/ST samples. Remarkably, 
the direction of expression differences between SP and 
intracranial tumours was the same in all 100 permutations 
as in the initial observation with complete data for all 557 
differentially expressed genes (Supplementary Figure 
2A). In addition, for these 557 differentially expressed 
genes, the median Pearson correlation of t-statistics with 
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the 100-permutated data was 0.913 (mean = 0.909, sd = 
0.012, 25th percentile = 0.906, 75th percentile = 0.918) 
(Supplementary Figure 2B) indicating sample imbalance 
had no impact on the observed differences between SP 
and intracranial tumours. To test whether these findings 
were replicable, and to further validate these results, we 
examined differential expression in an independent data 
set (DS2). The DS2 consisted of expression data generated 
with Affymetrix Human Exon ST 1.0 microarrays from 
tumor samples of 79 pediatric ependymoma cases (SP = 
4, PF/ST = 50/25). Though these arrays differ from the 
ones used in DS1, there was a positive correlation of test 
statistics for differential expression between DS1 and 
DS2 for the differentially expressed genes also present in 
the DS2 data (457 of 557; Pearson correlation r = 0.55, 
P < 2.2×10−16); the correlation remained significant 
(r = 0.27, P < 2.2×10−16) across all 14,097 genes common 
to both platforms after quality control (Supplementary 
Figure 3). Moreover, 84% of 457 genes in DS2 showed 
the same direction of expression differences between 
SP and intracranial tumours as in the initial cohort, DS1 
(Figure 1B), supporting the robustness of the differential 
expression results. Next, we ascertained whether these 
differentially expressed genes are specific for pSEPN. 
We therefore obtained expression data from six publicly 
available studies (Supplementary Table 2), selected those 
tumor samples of patients with age < 18 years from ST or 
PF EPNs (n = 223 primary tumours), and analysed using a 
random-effect model to integrate gene-specific expression 
changes between ST and PF in each individual study. We 
identified 628 genes that show high expression in pediatric 
ST tumours and 364 genes with high expression levels in 
PF tumours (Unpublished data). Remarkably, there was 
no significant overlap observed between differential 
expressed genes in pSEPN and pediatric ST tumours 
(12/628 genes overlapped, P = 0.97, Fisher’s exact test) 
or between pSEPN and pediatric PF tumours (14/364 
genes overlapped, P = 0.18, Fisher’s exact test). Thus, 
differential expression analysis produced robust and 
reproducible results, warranting further analysis.
Gene ontology highlights genes linked 
to developmental processes and 
mitochondrial metabolism
To obtain a functional overview, we annotated the 
upregulated genes in pSEPN separately, using WebGestalt 
2013 tool [17]. These genes are significantly enriched for 
a spectrum of gene ontology (GO) terms in biological 
processes category (Figure 2A and Supplementary Table 
3). Pediatric SEPN demonstrated increased expression of 
genes involved in anterior/posterior pattern specification 
(17 genes; FDR = 1.0×10−03), embryonic morphogenesis 
(26 genes; FDR = 1.5×10−03), tube development (23 
genes; FDR = 2.5×10−03), and epithelial cell development 
(8 genes; FDR = 8.7×10−03). In addition to development-
related processes, we uncovered novel pathways that had 
not been linked to pSEPN. For example, we found up-
Figure 1: Gene expression profiles define distinct characteristics of pediatric SEPN. (A) Volcano plot showing the number of 
significantly differentially expressed genes in pSEPN (FDR < 0.05). The x-axis represents expression fold change between pSEPN (n = 6) 
and pediatric intracranial ependymomas (n = 60) in log2 scale and the y-axis represents –log10 of false discovery rate (FDR). (B) Expression 
fold changes for all differentially expressed genes in this cohort are plotted on the x-axis against the fold changes (y-axis) for the same genes 
in the replicated dataset (DS2) with four SEPN and seventy-five intracranial ependymomas.
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regulation of genes involved in oxidative phosphorylation 
(9 genes; FDR = 1.5×10−03), cellular respiration (13 genes; 
FDR = 1.9×10−03), electron transport chain (12 genes; 
FDR = 3.1×10−03), and cofactor metabolic process (16 
genes; FDR = 3.5×10−03). The mitochondrial oxidative 
phosphorylation (OXPHOS) system consists of five 
protein complexes and genes encoding components of 
complex I (NDUFAB1, NDUFA8, NDUFB3, NDUFB5 
and NDUFB10), complex II (SDHD), complex V 
(ATP5H, ATP5J, ATP5O, ATP5S, ATP6V1G1 and 
PPA2), and coenzymes (COQ7 and COQ9) showed 
increased expression in pSEPN. In addition, we found 
that mitochondrial biogenesis genes, in particular, the 
mitochondrial ribosomal genes MRPL15, MRPL48, 
MRPL50, MRPS18C, MRPS33 and MRPS6, were also 
expressed at significantly higher levels in pSEPN when 
compared with pediatric intracranial ependymomas. 
Collectively, these results implicate mitochondrial 
metabolism and OXPHOS in the pathogenesis of pSEPN.
Next, we probed biological and disease pathways 
using the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database and found that metabolic, tight 
junction, ubiquitin mediated proteolysis, endocytosis, 
purine metabolism, and calcium-signalling pathways 
were enriched in genes differentially expressed pSEPN 
(Figure 2B). Together, these significantly over-represented 
pathways suggest that pSEPNs develop in the setting of 
complex biologic processes and point to perturbations in 
mitochondrial function and cellular metabolism as key 
underlying features.
Comparative gene expression analysis of 
pediatric and adult SEPN
To begin to determine whether transcriptional 
networks in pSEPN overlap with those in adult tumours, 
we compared the expression profiles of pediatric to adult 
SEPN (n = 6 for SP and n = 4/7 for PF/ST). Remarkably, 
87.5% of 400 differentially expressed genes were specific 
to adult SEPN, while only 12.5% were shared between 
adult and pediatric SEPN, suggesting distinct gene 
regulatory programs define these two tumour groups 
(Figure 3A and Supplementary Table 4). For example, 
CPA3 showed high expression with pediatric SEPN (log2 
fold change (FC): 2.54; FDR = 2.94×10−04) but not with 
adult SEPN (FC: 0.001; FDR = 0.99) when compared 
with intracranial tumours (Figure 3B). The shared list of 
up-regulated genes in adult and pediatric SEPN included 
genes involved in DNA damage and signal transduction 
resulting in induction of apoptosis (CHEK2), negative 
regulation of IGF1 receptor signalling pathway (ATXN1 
and CLIP), and extracellular matrix constituent secretion 
(CTGF) (Figure 3B and Supplementary Table 4). In 
addition, seven protein coding HOX genes and a non-
protein coding HOXB cluster antisense RNA 3 (HOXB-
AS3) showed significant changes in expression in both 
pediatric and adult SEPN (Supplementary Table 4). HOX 
genes from groups 5 to 13 show elevated expression in 
cervical and lumbar regions of the spinal cord [18], and 
higher expression levels of seven genes from this group 
in adult SEPN further validate the importance of HOX 
Figure 2: Summary of gene ontology (GO) biological processes and KEGG pathways derived from the enrichment 
analysis of upregulated genes in pSEPN. (A) X- and Y-axes represent a two-dimensional annotation space derived from a multi-
dimensional scaling procedure used on a matrix of GO terms’ semantic similarities. By employing this visualization method, similar 
biological categories will cluster together. Bubble color represents the p-value obtained from GO enrichment analysis and bubble size 
relates to the frequency of GO terms in the GO annotation database. (B) Results of enrichment analyses KEGG pathways for the upregulated 
genes in pSEPN is represented in the bar plots. We used the Hypergeometric test to calculate P values and used the FDR of 5% to obtain 
significantly enriched pathways.
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genes in EPN. Remarkably, no other HOX genes were 
found among the remaining 203 up-regulated genes 
specific to adult SEPN. Several differentially expressed 
HOX genes were significantly up regulated in pediatric, 
but not in adult SP EPN, including HOXA (A10, A11 and 
A13), HOXB (B13), and HOXD (D8, D9, D10 and D11) 
(Figure 4A). Interestingly, we also identified several genes 
whose expression was up-regulated in pediatric but down-
regulated in adult SEPN, including genes involved in 
developmental processes (ARX, CNTF, FOXE1, HOXD9 
and LHX9), genes associated with lipid (AMT, CERS3, 
HPGD and OXNAD1), carbohydrate (GTPBPB and 
PTGR1) and RNA metabolic processes (CSTF3, TLE4 and 
ZNF382), and regulation of cell proliferation (AGTR1).
Loss of chromosome 22 and monozygosity for 
22q with frequent mutations in a tumour suppressor 
gene, neurofibromin 2 (NF2) have been detected in the 
SEPN genome [10, 13]. In the current study, the NF2 
gene was downregulated in both pediatric and adult SP 
EPN compared to intracranial ependymomas; however, 
the change in expression was not significant after 
correction for multiple testing (Supplementary Figure 
4). To examine whether loss of regions on one or both 
chromosomes could repress expression of genes located 
on chromosome 22 in pSEPN, we performed the positional 
gene enrichment (PGE) analysis to identify chromosome 
regions significantly enriched in differentially expressed 
genes [19]. There were 91 significantly downregulated 
genes in pSEPN and PGE analysis showed enrichment 
of genomic regions on several chromosomes, but not on 
chromosome 22 (Supplementary Table 5). By contrast, 
down-regulated genes in adult SEPN show significant 
enrichment for several chromosomes, including genomic 
regions on chromosome 22 (20101693-20637217, 
FDR = 2.24×10−04; 20381828 – 20637217, FDR = 
8.79×10−04; 34267296 – 35113958, FDR = 4.95×10−03; 
and 44277383-45512816, FDR = 4.95×10−03). As a proof 
of the robustness of our findings, we plotted the change in 
expression (fold-change on log2 scale) between SEPN and 
intracranial ependymomas in both pediatric and adult for 
all chromosome 22 genes, and found similar qualitative 
findings (Figure 4B). We observed that chromosome 22 
has the highest percentage of down-regulated genes in 
adult SEPN (~84%) compared to pSEPN (~58%) and, in 
particular, the enriched q11 band contains genes DGCR2, 
HIC2, MED15, PPM1F and YPEL1 that were significantly 
down regulated in adult SEPN (FDR < 0.05). These data 
suggest that dosage imbalance of chromosome 22 genes 
occurs in adult SEPN, but not in pSEPN. Together, these 
findings illuminate distinct gene expression patterns 
of pSEPN versus adult SEPN and provide evidence for 
potentially pathogenic changes in gene expression.
Figure 3: Pediatric SEPNs show distinct expression characteristics from adult SEPNs. (A) Adult (x-axis) and pediatric 
(y-axis) moderated t-statistics of differential expression for each gene (point) are plotted when spinal EPNs were compared with intracranial 
ones. The number of these genes differentially expressed with both adult and pediatric (pink), in adult EPNs (green) and only in pediatric 
EPN (light brown). (B) Box plots showing log2 expression levels (y-axis) of representative (five) genes that show significant high expression 
only in pSEPN (top) and significant high expression in both pediatric and adult SEPN (bottom) when compared to pediatric intracranial 
ependymomas as well as to adult SEPN. PED SP (n = 6): pediatric spinal, PED intracranial (n = 60): pediatric intracranial, ADULT SP (n 
= 6): adult spinal, and ADULT intracranial (n = 11) ependymomas.
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Differential expression of miRNAs in 
pediatric SEPN
To obtain a comprehensive list of candidate 
miRNAs that are characteristic of pSEPN, we compared 
the expression of each miRNA in SEPN samples (n =6) 
with those of intracranial tumours (n = 43) obtained from 
pediatric ependymoma patients. Global expression was 
measured with the Agilent human miRNA microarray 
that contains probes for 723 human microRNAs and 
76 human viral microRNAs from the Sanger database 
v.10.1. After normalizing microarray data, we excluded 
all nonhuman miRNAs, and miRNAs not detected in 
10% of total samples, leaving 311 miRNAs detected. 
To find differentially expressed miRNAs between SP 
and intracranial sample groups, two-sample moderated 
t statistic was performed on each miRNA. There were 
six up- and four down-regulated miRNAs in SP relative 
to intracranial tumors (FDR < 0.05) (Table 1). Several 
differentially expressed miRNAs in pSEPN were already 
known to function as “oncomiRs” (has-miR-10b and 
has-miR-196a) or “tumour suppressors” (hsa-miR-26a 
and hsa-miR-124), suggesting their potential role in the 
pathogenesis of these tumors. miR-10b was the most 
significantly induced, displaying >10-fold increase in 
pSEPN. Another miR-10 family member, miR-10a, was 
Figure 4: Distinct expression patterns of HOX genes and Chromosome 22 genes in pediatric and adult SEPN. (A) 
Aberrant expression HOX genes in pediatric and adult SEPN. Schematic diagram of expression changes (fold change on log2) of HOX 
genes in pediatric (top) and adult (bottom) SEPN is displayed (green indicates under-expression whereas pink is for the over-expression 
in SEPN compared to intracranial ependymomas). HOX genes are arranged by paralogous group (1-13) in four clusters (A-D), each at 
a different chromosomal location. The expression of 15 HOX genes was significantly altered in pediatric whereas seven were found 
in adult SEPN (FDR < 0.05). In pediatric SEPN: HOXA7, 10, 11, and 13; HOXB6, 7, 8, and 13; HOXC6, 9, and 10; HOXD8, 9, 10, 
and 11 were overexpressed. In adult SEPN: HOXA7; HOXB6, 7, and 8; HOXC6, 9, and 10 were overexpressed. (B) Expression levels 
(log2) of chromosome 22 genes that are detected in our study for pediatric (left panel) and adult (right panel) SEPNs. Genes are sorted 
according to their position on the chromosome (x-axis) and colored according to the statistical significance of their expression level 
(y-axis). Significantly downregulated genes in SEPN (FDR < 0.05) are marked with blue, upregulated ones with red, and non-significant 
ones with grey. Normalized log2 expression values (dots) and kernel-smoothed expression values (purple line) are shown.
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also enriched (~ 4-fold). As miR-10a resides in the HOXB-
gene cluster on chromosome 17 and miR-10b resides in 
the HOXD-gene cluster on chromosome 2, it is likely 
that miR-10 family members play important roles in 
regulating multiple processes during brain development, 
and alterations in their functions may lead to initiation or 
progression of pSEPN.
Relationship between miRNA and mRNA 
expression changes
Protein-coding transcript levels can be post-
transcriptionally regulated by the activity of miRNA. These 
small RNA molecules silence mRNA translation through 
sequence-specific targeting. To understand miRNA-guided 
regulation, it is essential to uncover the downstream 
mRNA targets in addition to profiling miRNA identities. 
This prompted us to analyse miRNA-mRNA relationships 
in the context of pSEPN. We focused this miRNA-mRNA 
analysis on the 10 differentially expressed miRNAs 
that we identified above. We first used TargetScan [20], 
miRanda [21], and miRDB [22] databases to find putative 
miRNA targets based on sequence complementarity to 
mRNA 3’ UTR of reliably expressed protein-coding 
genes. We next compared the expression profiles between 
miRNA-mRNA pairs and selected the anti-correlated pairs 
with statistically significant association (FDR < 0.05). The 
combination of the correlation and target prediction filters 
yielded 159 miRNA-mRNA pairs (~ 6.6% of miRNA-
mRNA pairs detected from the expression data at FDR 
< 0.05), of which 56 pairs were related to miRNAs that 
were downregulated in pSEPN (Supplementary Table 6). A 
GO enrichment analysis on the set of 159 high-confidence 
miRNA targets indicated enrichment in broad categories, 
including developmental processes, multicellular organism 
signalling, cytoskeletal protein binding and transport 
functions, consistent with aberrant development in 
pSEPN and the regulatory role of the miRNA machinery 
in orchestrating these functions (Supplementary Figure 
5). Remarkably, the tumor suppressor miRNA, hsa-
miR-124, targeted the majority of detected mRNA targets 
(75% of 56) that were involved with developmental 
processes (EFNB3, NR4A3, PAX3 and SYNOP2), cell-
cell communication (AFF1, RALGPS2 and TSPAN6), 
and metabolic processes (CUL5, GRSF1, SGMS2, STK35 
and ZFAND3). The hsa-miR-153, which was the second 
most down-regulated miRNA in pSEPN, targets genes 
encoding transporter proteins (ITPR1, MATN2 and 
SLC44A1), calcium-binding protein (CIB2), transcription 
factor (CITED2), and a receptor, TGFBR2, which showed 
significant up-regulation in pSEPN (log2 Fold change, FC 
= 1.50, FDR = 0.034). Interestingly, Matrilins 2 (MATN2) 
was co-ordinately targeted by both hsa-miR-124 and hsa-
miR-153.
We next focused our attention on the putative targets 
of the most abundantly expressed miRNAs in pSEPN to 
Table 1: The dysregulated microRNAs in pediatric SEPN (n = 6) compared to pediatric intracranial ependymomas 
(n = 43)
miRNA ID FC (log2) Mean expression (log2) FDR
Up regulated    
hsa-miR-10b-5p 3.40 5.08 1.36×10−02
hsa-miR-196a-5p 2.55 2.66 1.36×10−02
hsa-miR-10a-5p 1.94 5.43 2.36×10−02
hsa-miR-144-5p 1.74 4.20 2.36×10−02
hsa-miR-23b-3p 1.22 10.38 2.36×10−02
hsa-miR-27b-3p 1.13 10.63 2.36×10−02
Down regulated    
hsa-miR-124-3p -3.34 6.19 4.55×10−02
hsa-miR-153-3p -2.40 5.61 4.56×10−02
hsa-miR-885-5p -2.18 5.98 2.36×10−02
hsa-let-7b-5p -1.05 12.49 5.33×10−02
hsa-miR-26a-5p -0.66 11.49 2.36×10−02
FC (log2): Fold change in expression between pediatric SP EPN and intracranial ependymomas on log2 scale; 
Mean expression (log2) across all tumor samples; and FDR: false discovery rate.
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increase our confidence in any possible miRNA-mRNA 
regulatory interactions. The putative mRNA targets of 
up-regulated miRNAs were highly enriched for synaptic 
transmission (CNTNAP2, DIRAS1, GPSM1, GRM3, 
HTT and SNAP25), chromatin modification (HDAC4, 
KDM4A, SS18L1 and TLK1), and negative regulation of 
transcription from RNA polymerase II promoter (HDAC4, 
NCOR2, NFIX, PKIA and SOX11). Interestingly, genes 
involved with cell differentiation (ACVR1C, CBFA2T3, 
ELAVL3, GPSM1 and PKDCC) were also repressed by 
upregulated miRNAs in pSEPN. The top most upregulated 
miRNA in pSEPN, hsa-miR-10b, and its closely related 
family member, hsa-miR-10a, cooperatively target several 
genes including those encoding synaptic cell adhesion 
molecule (CADM2) and histone deacetylase 4 (HDAC4) 
that play a critical role in transcriptional regulation, cell 
cycle progression, and developmental events (Figure 
5). The transcriptional co-repressor gene, CBFA2T3, 
stimulates mitochondrial respiration. The gene encoding 
Activin A receptor type 1C (ACVR1C), acts as an anti-
proliferative factor during early stages of oncogenesis, 
and is preferentially targeted by hsa-miR-23b and hsa-
miR-27b, which are located in one genomic cluster (miR-
23b/27b). The G-Protein Signalling Modulator 1 (GPSM1) 
and the protein kinase, PKDCC were targeted by hsa-
miR-23b, while the neural-specific RNA-binding protein, 
ELAVL3 was targeted by hsa-miR-10a (Figure 5).
DISCUSSION
Our comprehensive analysis on the pSEPN 
transcriptomics landscape provides novel insights into 
putative molecular mechanisms underlying pSEPN. Based 
on gene expression signatures, including both protein-
coding genes and miRNAs, we discovered significant up-
regulation in specific genes and their associated pathways 
in pSEPN when compared to pediatric intracranial 
ependymoma or adult EPN. Moreover, the differential 
expression of a subset of genes expressed in pSEPN 
compared to pediatric intracranial EPN was validated 
in an independent cohort of pediatric EPNs. Together, 
these findings suggest that this gene signature is therefore 
likely to be contributes to the underlying biology of these 
tumours.
Surprisingly, among genes with increased expression 
in pSEPN, there was strong enrichment for mitochondrial 
genes (63 genes; P = 2.58×10−08) related to oxidative 
phosphorylation, electron transport chain and cofactor 
metabolic process, all of which had not been previously 
linked to pSEPN. The oxidative phosphorylation 
(OXPHOS) system is composed of NADH:ubiquinone 
oxidoreductase (complex I), succinate dehydrogenase 
(SDH; complex II), coenzyme Q cytochrome c oxidase 
(complex III), cytochrome c oxidase (COX; complex IV), 
ATP synthase (complex V), and 2 electron carriers, namely 
Figure 5: Networks of miRNA-mRNA target interactions in pediatric SEPN. Two highly connected sub-networks from the 
inferred network of pediatric EPNs comprising 159 putative target interactions between miRNAs and mRNAs. Edge width represents 
strength of Spearman rank correlation for a given miRNA-mRNA pair, green colour represents evidence of significant downregulation in 
pSEPN.
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cytochrome c and coenzyme Q [23]. Genes encoding 
protein complexes I, II and V as well as coenzymes and 
proteins involved in mitochondrial biogenesis showed 
elevated expression in pSEPN. In addition, contrary to 
the results of recently published study [24], none of the 
genes characteristic of the ‘Warburg phenotype’ (HIF1A: 
FC = −0.02, FDR = 0.970; HK1: FC = −0.15, FDR = 
0.727; HK2: FC = −1.07, FDR = 0.197; and PDK1: FC 
= −0.39, FDR = 0.745) showed increased expression in 
pSEPN when compared to pediatric intracranial EPN. It 
should be emphasized that the prior study on ‘Warburg 
phenotype’ assessed 35 SEPNs (~80% from adult 
ependymoma patients), comparing gene expression in the 
myxopapillary ependymoma (MPE) subtype to that of 
Grade II SEPNs, and found that genes related to ‘Warburg 
phenotype’ were up-regulated in MPE [24]. Together, 
our findings demonstrate enhanced expression of genes 
involved in oxidative energy metabolism with a shift away 
from glycolytic genes towards those involved in OXPHOS 
in pSEPN compared to pediatric intracranial EPN. 
Investigations aimed at understanding the mechanisms of 
this program deserve further attention.
As expected, we also found strong enrichment of 
developmental genes in pSEPN, including those associated 
with anterior/posterior pattern specification, embryonic 
morphogenesis, tube development, and epithelial cell 
development. Notably, HOX genes that play fundamental 
roles in specifying the anterior-posterior (A-P) body 
patterning and spinal cord development were significantly 
upregulated in pSEPN. The 39 human HOX genes are 
divided into four groups (A–D), which are further divided 
into paralogue groups (1–13) based on their position 
numbered from the 3’ to the 5’ end (1 to 13), with the 3′ end 
genes expressed the earliest and linked to the development 
of rostral structures whereas the 5′ end genes linked to the 
development of more caudal structures [18]. It is interesting 
to note that all HOX genes (6 to 13) that showed high 
expression in pSEPN correspond to HOX genes that are 
associated with caudal structures (Figure 3). It is also of 
interest that the expression patterns of some of these HOX 
genes located closest to the 5’ end of the cluster are preserved 
in pediatric and adult SEPN, indicating spatial relationships 
of HOX-expressing spinal cord remain unchanged during the 
course of development. This characteristic expression pattern 
of HOX genes in adult and pediatric SEPNs further support 
their important role in regional identity and the maintenance 
of spinal cord specificity. Genes in the HOX family have 
been the focus of investigation in a variety of malignancies, 
as they play important roles in stem cell renewal, cellular 
fate determination, and body-pattern development [25, 26]. 
Specifically, HOX cluster 10 −13 is associated with normal 
development of the lumbosacral region. Moreover, prior 
studies revealed oncogenic function of HOXA11, HOXA13, 
and HOXD11 in other cancers, implicating these genes in 
the pathogenesis of SEPN, although further studies will be 
needed to elucidate their role in this setting.
Emerging evidence suggests that pediatric and adult 
central nervous system tumors are biologically distinct 
entities [27], and our results provide additional support for 
this concept. The relatively low numbers of differentially 
expressed genes that were shared between adult and 
pediatric SEPN indicate distinct transcriptional programs. 
In comparison to adult ependymomas, pSEPN tumors 
show a remarkable convergence on genes associated with 
developmental processes and mitochondrial metabolism. 
Indeed, subsets of genes that are typically repressed in 
adult EPN are overexpressed in pSEPN. In contrast, 
deletions in chromosome 22, including NF2 mutations, are 
among the most commonly reported genetic abnormalities 
in SEPN [10, 13]. Our analysis suggested that loss of 
chromosome 22 occurs in adult rather than in pSEPN, 
which likely has important functional consequences in 
the pathogenesis of adult SEPN. The differences between 
pediatric and adult SEPN may be partly related to the 
limitations inherent to the rather small number of cases 
in both comparisons, particularly the lower incidence 
of intracranial EPN in adults. There were also a smaller 
number of SEPN in pediatric cases. These issues need to 
be addressed in the future by studying a large series of 
cases using uniform criteria.
Because pediatric CNS tumors have fewer 
mutational events relative to their adult counterparts, 
it is critical to investigate factors that regulate the 
transcriptome, such as miRNAs, in order to gain 
a comprehensive understanding of tumorigenesis. 
Differential expression analysis uncovered six miRNAs 
whose expression levels are elevated in pSEPN. Of 
these, three (miR-10a, miR-144* and miR-196a) reside 
on chromosome 7 and two on chromosome 9 (miR-23b 
and miR-27b). Precursors of miR-10a and miR-196a (~50 
kb apart) and miR-23b and miR-27b (0.141 kb apart) are 
closely clustered in the genome, suggesting common 
upstream transcriptional controls. As miR-10a shares the 
same seed sequence with miR-10b, the most abundant and 
differentially expressed miRNA in pSEPN, and reside 
within the HOX gene cluster (10a in HOXB whereas 10b 
in HOXD), it is likely that miR-10 family members play 
key roles during development. Dysregulation of miR-10 
family members has been reported for several human 
cancers, including up-regulation of both miR-10a and 
miR-10b in glioblastoma and anaplastic astrocytomas, in 
some cases reaching more than a 100-fold overexpression, 
suggesting an oncogenic potential in brain tumors [28, 29].
Integration of miRNAs and mRNA expression 
profiles with the targeting information obtained from 
databases allowed us to identify a set of regulatory miRNA-
mRNA pathways that may play a role in the pathogenesis of 
pSEPN. For the 159 high-confidence miRNA-mRNA target 
pairs, assignment of GO terms indicated that the pSEPN 
miRNAs extensively regulate developmental processes, 
especially cell differentiation, nervous system development, 
and anatomical structure development. Among distinct 
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molecular functions, the pSEPN miRNAs target a large 
number of transcripts responsible for cytoskeletal protein 
binding, kinase activity, and ion transporter activity. Genes 
located in membrane and synapse, as well as neuron 
projection that are crucial in regulating the transmission 
of information through the spinal dorsal horn occupy 
the largest proportion of miRNA targets in the “cellular 
component” category. Interactions of individual miRNAs 
are summarized in Supplementary Table 5, which provides 
clues to how a particular miRNA may contribute to 
regulating transcripts, which in turn, distinguish pSEPN 
from pediatric intracranial EPN. Several individual miRNA-
target relationships in the high-confidence set illustrate the 
potential relevance to the developmental and metabolic 
processes in the pSEPN. miR-124, which is one of the most 
strongly and uniformly down-regulated miRNAs in brain 
neoplasia, targets the GRSF1 transcript (Supplementary 
Table 5). The protein encoded by this gene belongs to a 
family of ubiquitously expressed RNA-binding proteins that 
play key roles in all steps of posttranscriptional regulation of 
RNAs. Loss of GRSF1 results in a specific protein synthesis 
defect with failure to assemble the required levels of 
oxidative phosphorylation complexes, implicating GRSF1 
as a key regulator of posttranscriptional mitochondrial gene 
expression [30]. Additionally, hsa-miR-124-3p was shown 
to target the tetraspanin 6 (TSPAN6) gene, which encodes 
a cell surface glycoprotein protein that mediates several 
signal transduction events. TSPAN6 interacts with nuclear 
receptor subfamily 4 group A member 3 (NR4A3) protein, 
which modulates numerous processes, including CNS 
development, cell differentiation and lipid metabolism. The 
protein encoded by the MATN2 gene is involved in axonal 
guidance and was significantly elevated in pSEPN (log2 fold 
change, FC = 2.43, FDR = 0.043). MATN2 is a putative 
target of both hsa-miR-124-3p and hsa-miR-153-3p. Of 
note, the MATN2 protein is elevated in NF1-associated 
pilocytic astrocytoma with an unusually aggressive clinical 
phenotype [31]; it will therefore be interesting to further 
examine the effects of MATN2 and potential regulation by 
miR-124 and miR-153 in SEPN. Future efforts are warranted 
to elucidate the functional roles of the novel transcriptional 
networks revealed by our studies.
When studying a rare cancer such as pSEPN, 
adequate sample size is an inherent challenge, and was a 
limitation of this study. Nonetheless, our study revealed 
that pSEPN is associated with increased expression of 
genes involved in oxidative phosphorylation. As expected, 
we also found overexpression of diverse developmental 
pathway genes. In addition, there was a striking up-
regulation in expression of the oncogenic miRNA, miR-
10b, and its closely related family member, miR-10a in 
pSEPN. This integrated miRNA-mRNA analysis reveals 
a comprehensive genomic landscape of pSEPN and 
provides the groundwork necessary to design larger, multi-
centre studies to validate the cancer transcriptome as well 
as uncover novel biomarkers and therapeutic targets for 
pSEPN.
MATERIALS AND METHODS
Microarray data acquisition and analysis
Both mRNA and miRNA expression profiling of 
pediatric ependymoma were part of our published study 
[9]. The raw data was obtained from the Gene Expression 
Omnibus (GEO) database (GSE21687). This study contains 
tumor samples from 66 pediatric EPN patients (SP: 6 and 
PF/ST: 30/30) with a mean age of 6.47 (+ 4.60) years. The 
mRNA data were generated using the Affymetrix Human 
Genome U133 Plus 2.0 arrays. Expression intensity values 
were calculated at probeset level for the 66 CEL files 
using the robust multi-array average (RMA) method [32]. 
Probesets that are ‘absent’ (present/absent call using MAS5) 
in all samples were filtered out from the analysis. Expression 
values were mapped from probeset to unique gene and 
the probeset with the highest mean expression value was 
selected when multiple probesets were mapped to the same 
gene. The final filtering step left a total of 18,365 genes. 
For the validation of differentially expressed genes, we used 
an additional dataset (GSE27279) of mRNA microarrays 
from 79 pediatric EPN patients (SP = 4, PF/ST = 50/25) 
with a mean age of 5.93 (+ 4.70) years [11]. The data were 
generated using the Affymetrix human Exon 1.0 ST arrays. 
We used the Affymetrix Power Tools to generate gene-level 
(core meta-probeset) expression values from raw CEL 
files. Arrays were normalized using RMA, which included 
RMA background correction, quantile normalization, log 
transformation, and probeset summarization. Detection 
above background (DABG) was performed at both the 
probe and the probeset level using GC-matched background 
probes, and low variance probesets were excluded (17,001 
genes). To identify differentially expressed genes, linear 
models were fitted with Bioconductor’s limma package 
[33], which uses a moderated t-statistic based on empirical 
Bayesian method and the P values were adjusted using 
Benjamini and Hochberg FDR procedure [34]. In addition, 
we used Rank Product, a nonparametric method designed 
for experiments with a small number of replicates [35]. 
Differential expression was defined for genes with FDR < 
0.05.
miRNA expression was profiled by Agilent 
microarrays, and processed and normalized using the 
AgiMicroRna R package (using between-array quantile 
normalization) [36]. To filter miRNAs with very low 
expression across most EPN samples, we removed 
miRNAs that were detected in < 25% of samples (using 
the ‘detected’ flag in the microarray data sets). The final 
expression datasets contain 300 miRNAs. We used a 
moderated t-statistic based on empirical Bayesian method 
to identify differentially expressed genes or miRNAs 
between pediatric spinal and other ependymomas [33]. 
The p-values obtained from moderated t-test were 
corrected for multiple hypotheses using Benjamini and 
Hochberg algorithm [34]. The corrected P value, False 
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Discovery Rate (FDR) less than 5% was used to select the 
differentially expressed genes or miRNAs.
Gene set enrichment and pathway analysis
The over-representation analyses for Gene Ontology 
(GO) terms, Kyoto Encyclopedia of Genes and Genomes 
(KEGG), and Panther pathways, were carried out with 
WebGestalt 2013 tool [17]. The REVIGO software was 
used to summarize and visualize significant GO terms 
in a two-dimensional space as a scatter plot, derived 
by applying multidimensional scaling to a matrix of 
the GO terms’ semantic similarities using the SimRel 
algorithm [37]. In the scatter plot, bubble colour indicates 
the p-value obtained from the WebGestalt’s over-
representation analysis and size indicates the frequency 
of the GO term in the underlying GO database (bubbles 
of more general terms are larger). The overlap between 
differentially expressed genes and chromosomal positions 
was investigated using the positional gene enrichment 
analysis tool [19]. The significance of statistically 
enriched functional categories, pathways, and gene sets 
was estimated either with hypergeometric test or with 
Fisher’s exact test and the p-values were corrected for the 
multiple comparisons by estimating the FDR.
miRNA network analysis
Human miRNA target predictions were obtained 
from three different databases: miRanda-miRSVR (August 
2010 release, http://microrna.org), TargetScan (Release 7.0, 
August 2015, http://targetscan.org) and mirDB (Version 5, 
Release date Auguest 2014, http://mirdb.org) [20–22]. We 
used miRanda-miRSVR scores, evolutionary conservation 
scores, and TargetScan context scores aggregated per gene 
and miRNA. Predicted miRNA targets are defined by the 
intersection of miRanda (score < −0.5 and conservation 
score > 0.5), TargetScan (context-score < −0.2) and 
miRDB (Target score > 50), unless otherwise stated. We 
used these thresholds to obtain a high-confidence list 
of predicted miRNA-target interactions. To identify the 
functional regulations from miRNAs to mRNAs, we 
combined both the computational target predictions at the 
sequence level and the inverse expression relationships 
between miRNAs and mRNAs in the context of EPN. The 
Spearman rank correlation coefficients were calculated 
for each miRNA–mRNA pair, p-values were corrected 
for multiple hypotheses, and significant correlations were 
selected at FDR < 0.05. Finally, the functional regulations 
were detected using miRNAs and genes characterized by 
(i) the strongest targets, which have the highest predicted 
targeting efficacy (ii) the most conserved target sites, which 
are more likely to have conserved physiological roles, but 
may not include newly evolved targets with species-specific 
functions, and (iii) strong correlation from miRNA-mRNA 
expression profiles.
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